Beverly A. Teicher
贝弗利·泰谢尔
PhD
Senior Investigator, Developmental Therapeutics Branch发育治疗学部高级研究员
👥Biography 个人简介
Beverly Teicher is a leading authority on tumor microvasculature and antiangiogenic combination therapy at the NCI. Her laboratory established key preclinical frameworks for combining antiangiogenic agents with chemotherapy and radiation, demonstrating how microvessel density affects tumor drug resistance and treatment response.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Antiangiogenic Combination Strategies
Demonstrated that antiangiogenic agents combined with conventional chemotherapy overcome hypoxia-mediated drug resistance, establishing preclinical models still used in translational oncology.
Tumor Microvasculature and Drug Delivery
Characterized how abnormal tumor microvasculature creates hypoxic gradients that limit chemotherapy penetration, informing vessel-targeting combination strategies.
Representative Works 代表性著作
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Journal of the National Cancer Institute Monographs (2001)
Comprehensive analysis of how antiangiogenic interventions influence not only tumor growth but also invasion and metastatic dissemination.
Tumor vascularity: a histological measure of angiogenesis and hypoxia
Cancer Research (1994)
Established quantitative histological methods for assessing tumor microvessel density that became standard tools in antiangiogenic drug evaluation.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 贝弗利·泰谢尔 的研究动态
Follow Beverly A. Teicher's research updates
留下邮箱，当我们发布与 Beverly A. Teicher（National Cancer Institute (NCI)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment